Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Developmental delay | Early neurologic delay may occur with seizures and movement difficulty. | Delay and intellectual disability occur with variable congenital features. | Moderate |
| Seizures | Seizures are a described neurologic feature; frequency is not established. | Seizures are not specifically established by the supplied description. | Moderate |
| Congenital features | Primarily a metabolic neurologic disorder, not a defined malformation syndrome. | Various congenital features may accompany the chromosomal deletion. | High |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Young child with seizures and suspected serine deficiency
Fits the metabolic description and early-childhood onset axis.
Moderate
Amino-acid testing suggests low serine
Supports consideration, but an abnormal result is not itself a diagnosis.
Moderate
A potentially treatable metabolic cause is being sought
Serine supplementation and anticonvulsants are described; doses are not specified.
Moderate
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with congenital or dysmorphic findings
Aligns with the described chromosomal microdeletion phenotype.
Moderate
Microarray identifies missing 3q13 material
Supports the genetic condition when a clinician correlates the finding.
High
Variable-age presentation without a serine-pathway pattern
Onset is listed as variable and the category is genetic.
Low
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Plasma or CSF amino acids | May show low serine; no cutoff is supplied. | Not expected to define the deletion. | A low result suggests a metabolic disorder and needs confirmation. |
| PHGDH genetic or enzyme testing | Pathogenic change or reduced activity may support diagnosis. | Does not identify a 3q13 deletion. | Specialist interpretation is required. |
| Chromosomal microarray | Not the primary test for this enzyme deficiency. | May detect missing 3q13 material. | A deletion requires clinical correlation and is not a metabolic diagnosis. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Potentially severe chronic neurologic disorder; individual prognosis is not established.
- Factors
- Recognition, seizure control, and response to serine-directed care may influence outcome.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Described as moderate but variable chronic developmental condition.
- Factors
- Deletion findings, congenital features, and available support may affect function.
Time frame: Early childhood for the metabolic disorder; variable recognition for the deletion; follow-up is long-term.
Etiology, severity, comorbidities, and specialist care. No mortality figures are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | A recognized possible neurologic complication. Not established from the supplied source. Seizure effects vary and management must be individualized. |
| Intellectual or developmental impairment | Impairment may be severe, but individual outcome is uncertain. Intellectual disability is described with variable severity. No comparative rates or mortality data are supplied. |
| Congenital anomalies | Not a defining feature in the supplied description. Various congenital features may occur. Specific anomaly types and frequencies are not established. |
Patient education highlights
- HighDifferent causes
One condition affects serine metabolism; the other results from missing chromosome 3q13 material.
- HighTest interpretation
An abnormal laboratory or genetic result needs clinician review and is not automatically a final diagnosis.
- MediumLong-term care
Both are chronic. Metabolic treatment and developmental or congenital support are individualized.